[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534507":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":72,"centralContacts":76,"locations":85,"responsibleParty":416,"collaborators":419,"id":423,"slug":424,"hasResults":425,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":71,"eligibilityCriteria":429,"healthyVolunteers":425,"sex":430,"minAge":431,"maxAge":432,"enrollmentInfo":433,"targetDuration":71,"studyType":436,"phases":437,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":88,"whyStopped":71,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":460},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,18,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Reduced-dose radiotherapy group","EXPERIMENTAL","All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg\u002Fm2 day 1, 8 + cisplatin 80 mg\u002Fm2 day 1 + camrelizumab 200 mg day 1) followed by reduced-dose intensity-modulated radiation therapy (IMRT; 6360cGy, 30 fractions, 5 fractions\u002Fweek, 1 fraction\u002Fday). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg\u002Fm2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles.",[13,14,15,16,17],"Drug: PD-1 blocking antibody","Drug: Gemcitabine","Drug: Cisplatin (80 mg\u002Fm2)","Radiation: Reduced-dose Intensity-modulated radiotherapy","Drug: Cisplatin (100 mg\u002Fm2)",{"label":19,"type":20,"description":21,"interventionNames":22},"Conventional-dose radiotherapy group","ACTIVE_COMPARATOR","All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg\u002Fm2 day 1, 8 + cisplatin 80 mg\u002Fm2 day 1 + camrelizumab 200 mg day 1) followed by conventional-dose intensity-modulated radiation therapy (IMRT; 6996cGy, 33 fractions, 5 fractions\u002Fweek, 1 fraction\u002Fday). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg\u002Fm2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles.",[13,14,15,23,17],"Radiation: Conventional-dose Intensity-modulated radiotherapy",{"label":25,"type":6,"description":26,"interventionNames":27},"Not-Randomized population","All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg\u002Fm2 day 1, 8 + cisplatin 80 mg\u002Fm2 day 1 + camrelizumab 200 mg day 1) followed by conventional-dose intensity-modulated radiation therapy (IMRT; 6996cGy, 33 fractions, 5 fractions\u002Fweek, 1 fraction\u002Fday). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg\u002Fm2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles. Besides, all the participants should also receive metronomic adjuvant capecitabine chemotherapy (capecitabine 650 mg\u002Fm2 p.o. BID 1 year) immediately after the completion of concurrent chemoradiotherapy.",[13,14,15,23,17,28],"Drug: Capecitabine",[30,37,43,49,56,62,67],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","PD-1 blocking antibody","1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.\n2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.",[19,25,9],[36],"Camrelizumab",{"type":31,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Gemcitabine","Gemcitabine as induction chemotherapy, 1000 mg\u002Fm2 day 1, 8 per cycle, every 3 weeks for 3 cycles.",[19,25,9],[42],"GEM",{"type":31,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"Cisplatin (80 mg\u002Fm2)","Cisplatin as induction chemotherapy, 80 mg\u002Fm2 day 1 per cycle, every 3 weeks for 3 cycles.",[19,25,9],[48],"DDP",{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"RADIATION","Reduced-dose Intensity-modulated radiotherapy","1. Definitive IMRT, 30 fractions, 5 fractions\u002Fweek, 1 fraction\u002Fday\n2. Radiotherapy dose: pGTV: 6360cGy\u002F30F; pCTV1: 5460cGy\u002F30F; pCTV2: 4920cGy\u002F30F.",[9],[55],"Reduced-dose IMRT",{"type":50,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"Conventional-dose Intensity-modulated radiotherapy","1. Definitive IMRT, 33 fractions, 5 fractions\u002Fweek, 1 fraction\u002Fday\n2. Radiotherapy dose: pGTV: 6996cGy\u002F33F; pCTV1: 6006cGy\u002F33F; pCTV2: 5412cGy\u002F33F.",[19,25],[61],"Conventional-dose IMRT",{"type":31,"name":63,"description":64,"armGroupLabels":65,"otherNames":66},"Cisplatin (100 mg\u002Fm2)","Cisplatin as concurrent chemotherapy, 100 mg\u002Fm2 day 1 per cycle, every 3 weeks for 2 cycles",[19,25,9],[48],{"type":31,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"Capecitabine","Metronomic adjuvant capecitabine chemotherapy: 650 mg\u002Fm2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.",[25],null,[73],{"name":74,"affiliation":5,"role":75},"Jun Ma","PRINCIPAL_INVESTIGATOR",[77,81],{"name":74,"role":78,"phone":79,"phoneExt":71,"email":80},"CONTACT","+862087343469","majun2@mail.sysu.edu.cn",{"name":82,"role":78,"phone":83,"phoneExt":71,"email":84},"Kai-Bin Yang","+8613725368062","yangkb@sysucc.org.cn",[86,103,115,128,143,158,168,180,192,201,216,231,244,259,268,279,297,308,321,330,346,354,367,379,392,404],{"facility":87,"status":88,"city":89,"state":90,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":98,"contacts":99},"Fujian Cancer Hospital","RECRUITING","Fuzhou","Fujian","China","CN",{"type":94,"coordinates":95},"Point",[96,97],119.30611,26.06139,{"lat":97,"lon":96},[100,102],{"name":101,"role":78,"phone":71,"phoneExt":71,"email":71},"Chuan-Ben Chen",{"name":101,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":104,"status":88,"city":105,"state":90,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"The First Affiliated Hospital of Xiamen University","Xiamen",{"type":94,"coordinates":107},[108,109],118.08187,24.47979,{"lat":109,"lon":108},[112,114],{"name":113,"role":78,"phone":71,"phoneExt":71,"email":71},"San-Gang Wu",{"name":113,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":116,"status":88,"city":117,"state":118,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Dongguan People's Hospital","Dongguan","Guangdong",{"type":94,"coordinates":120},[121,122],113.74866,23.01797,{"lat":122,"lon":121},[125,127],{"name":126,"role":78,"phone":71,"phoneExt":71,"email":71},"Zhi-Gang Liu",{"name":126,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":129,"status":88,"city":130,"state":118,"zip":131,"country":91,"countryCode":92,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"The First People's Hospital of Foshan","Foshan","528000",{"type":94,"coordinates":133},[134,135],113.13148,23.02677,{"lat":135,"lon":134},[138,142],{"name":139,"role":78,"phone":140,"phoneExt":71,"email":141},"Gui-Chao Liu","8618038865028","490690@qq.com",{"name":139,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":144,"status":88,"city":145,"state":118,"zip":146,"country":91,"countryCode":92,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Sun Yat-Sen University Cancer Center","Guangzhou","510060",{"type":94,"coordinates":148},[149,150],113.25,23.11667,{"lat":150,"lon":149},[153,154,155,156],{"name":74,"role":78,"phone":79,"phoneExt":71,"email":80},{"name":82,"role":78,"phone":83,"phoneExt":71,"email":84},{"name":74,"role":75,"phone":71,"phoneExt":71,"email":71},{"name":82,"role":157,"phone":71,"phoneExt":71,"email":71},"SUB_INVESTIGATOR",{"facility":159,"status":88,"city":145,"state":118,"zip":160,"country":91,"countryCode":92,"cosmosGeoPoint":161,"geoPoint":163,"contacts":164},"The Affiliated Panyu Central Hospital of Guangzhou Medical University","511400",{"type":94,"coordinates":162},[149,150],{"lat":150,"lon":149},[165,167],{"name":166,"role":78,"phone":71,"phoneExt":71,"email":71},"Guo-Rong Zou",{"name":166,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":169,"status":88,"city":170,"state":118,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Cancer Hospital of Shantou University Medical College","Shantou",{"type":94,"coordinates":172},[173,174],116.67876,23.35489,{"lat":174,"lon":173},[177,179],{"name":178,"role":78,"phone":71,"phoneExt":71,"email":71},"Chuang-Zhen Chen",{"name":178,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":181,"status":88,"city":182,"state":118,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"Affiliated Hospital of Guangdong Medical University","Zhanjiang",{"type":94,"coordinates":184},[185,186],110.38749,21.23391,{"lat":186,"lon":185},[189,191],{"name":190,"role":78,"phone":71,"phoneExt":71,"email":71},"Hai-Qing Luo",{"name":190,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":193,"status":88,"city":182,"state":118,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":194,"geoPoint":196,"contacts":197},"Guangdong Nongken Central Hospital",{"type":94,"coordinates":195},[185,186],{"lat":186,"lon":185},[198,200],{"name":199,"role":78,"phone":71,"phoneExt":71,"email":71},"Rui-Wen Huang",{"name":199,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":202,"status":88,"city":203,"state":204,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Cancer Hospital of Guangxi Medical University","Nanning","Guangxi",{"type":94,"coordinates":206},[207,208],108.31667,22.81667,{"lat":208,"lon":207},[211,214],{"name":212,"role":78,"phone":71,"phoneExt":71,"email":213},"Xiao-Dong Zhu, MD","zhuxiaodong83@163.com",{"name":215,"role":75,"phone":71,"phoneExt":71,"email":71},"Xiao-Dong Zhu",{"facility":217,"status":88,"city":218,"state":219,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":220,"geoPoint":224,"contacts":225},"Cancer Hospital of Guizhou Medical University","Guiyang","Guizhou",{"type":94,"coordinates":221},[222,223],106.71667,26.58333,{"lat":223,"lon":222},[226,229],{"name":227,"role":78,"phone":71,"phoneExt":71,"email":228},"Feng Jin, MD","jinf8865@yeah.net",{"name":230,"role":75,"phone":71,"phoneExt":71,"email":71},"Feng Jin",{"facility":232,"status":88,"city":233,"state":234,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":235,"geoPoint":239,"contacts":240},"The Second Affiliated Hospital of Hainan Medical University","Haikou","Hainan",{"type":94,"coordinates":236},[237,238],110.34651,20.03421,{"lat":238,"lon":237},[241,243],{"name":242,"role":78,"phone":71,"phoneExt":71,"email":71},"Yue-Can Zeng",{"name":242,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":245,"status":88,"city":246,"state":247,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"Hubei Province Cancer Hosiptal","Wuhan","Hubei",{"type":94,"coordinates":249},[250,251],114.26667,30.58333,{"lat":251,"lon":250},[254,257],{"name":255,"role":78,"phone":71,"phoneExt":71,"email":256},"De-Sheng Hu, M.D.","hds_005@163.com",{"name":258,"role":75,"phone":71,"phoneExt":71,"email":71},"De-Sheng Hu",{"facility":260,"status":88,"city":246,"state":247,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":261,"geoPoint":263,"contacts":264},"Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology",{"type":94,"coordinates":262},[250,251],{"lat":251,"lon":250},[265,267],{"name":266,"role":78,"phone":71,"phoneExt":71,"email":71},"Guang-Yuan Hu",{"name":266,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":269,"status":88,"city":246,"state":247,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":270,"geoPoint":272,"contacts":273},"Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology",{"type":94,"coordinates":271},[250,251],{"lat":251,"lon":250},[274,277],{"name":275,"role":78,"phone":71,"phoneExt":71,"email":276},"Kun-Yu Yang, MD","yangkunyu@medmail.com.cn",{"name":278,"role":75,"phone":71,"phoneExt":71,"email":71},"Kun-Yu Yang",{"facility":280,"status":88,"city":281,"state":282,"zip":283,"country":91,"countryCode":92,"cosmosGeoPoint":284,"geoPoint":288,"contacts":289},"Hunan Cancer Hospital","Changsha","Hunan","410000",{"type":94,"coordinates":285},[286,287],112.97087,28.19874,{"lat":287,"lon":286},[290,293,295],{"name":291,"role":78,"phone":71,"phoneExt":71,"email":292},"Ya-Qian Han","hanyaqiancs@163.com",{"name":294,"role":75,"phone":71,"phoneExt":71,"email":71},"Ya-qian Han",{"name":296,"role":157,"phone":71,"phoneExt":71,"email":71},"Feng Liu",{"facility":298,"status":88,"city":281,"state":282,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":299,"geoPoint":301,"contacts":302},"Xiangya Hospital Central South University",{"type":94,"coordinates":300},[286,287],{"lat":287,"lon":286},[303,306],{"name":304,"role":78,"phone":71,"phoneExt":71,"email":305},"Liang-Fang Shen, MD","slf1688@sina.com",{"name":307,"role":75,"phone":71,"phoneExt":71,"email":71},"Liang-Fang Shen",{"facility":309,"status":88,"city":310,"state":311,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":312,"geoPoint":316,"contacts":317},"Jiangsu Cancer Hospital","Nanjing","Jiangsu",{"type":94,"coordinates":313},[314,315],118.77778,32.06167,{"lat":315,"lon":314},[318,320],{"name":319,"role":78,"phone":71,"phoneExt":71,"email":71},"Li Yin",{"name":319,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":322,"status":88,"city":310,"state":311,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":323,"geoPoint":325,"contacts":326},"Jiangsu Provinee Hospital of Chinese Medicine",{"type":94,"coordinates":324},[314,315],{"lat":315,"lon":314},[327,329],{"name":328,"role":78,"phone":71,"phoneExt":71,"email":71},"Jing Yan",{"name":328,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":331,"status":88,"city":332,"state":333,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":334,"geoPoint":338,"contacts":339},"Jiangxi Cancer Center","Nanchang","Jiangxi",{"type":94,"coordinates":335},[336,337],115.85306,28.68396,{"lat":337,"lon":336},[340,342,344,345],{"name":341,"role":78,"phone":71,"phoneExt":71,"email":71},"Jin-Gao Li",{"name":343,"role":78,"phone":71,"phoneExt":71,"email":71},"Xiao-Chang Gong",{"name":341,"role":75,"phone":71,"phoneExt":71,"email":71},{"name":343,"role":157,"phone":71,"phoneExt":71,"email":71},{"facility":347,"status":88,"city":348,"state":349,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":71,"geoPoint":71,"contacts":350},"The First Affiliated Hospital of Xian Jiaotong University","Xian","Shanxi",[351,353],{"name":352,"role":78,"phone":71,"phoneExt":71,"email":71},"Rui Liu",{"name":352,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":355,"status":88,"city":356,"state":357,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":358,"geoPoint":362,"contacts":363},"Sichuan Cancer Hospital","Chengdu","Sichuan",{"type":94,"coordinates":359},[360,361],104.06667,30.66667,{"lat":361,"lon":360},[364,366],{"name":365,"role":78,"phone":71,"phoneExt":71,"email":71},"Shi-Chuan Zhang",{"name":365,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":368,"status":88,"city":356,"state":357,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":369,"geoPoint":371,"contacts":372},"West China Hospital，Sichuan University",{"type":94,"coordinates":370},[360,361],{"lat":361,"lon":360},[373,375,377,378],{"name":374,"role":78,"phone":71,"phoneExt":71,"email":71},"Nian-Yong Chen",{"name":376,"role":78,"phone":71,"phoneExt":71,"email":71},"Lei Liu",{"name":374,"role":75,"phone":71,"phoneExt":71,"email":71},{"name":376,"role":157,"phone":71,"phoneExt":71,"email":71},{"facility":380,"status":88,"city":381,"state":382,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":383,"geoPoint":387,"contacts":388},"Zhejiang Cancer Hospital","Hangzhou","Zhejiang",{"type":94,"coordinates":384},[385,386],120.16142,30.29365,{"lat":386,"lon":385},[389,391],{"name":390,"role":78,"phone":71,"phoneExt":71,"email":71},"Xiao-Zhong Chen",{"name":390,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":393,"status":88,"city":394,"state":71,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":395,"geoPoint":399,"contacts":400},"Chongqing Cancer Hospital","Chongqing",{"type":94,"coordinates":396},[397,398],106.55771,29.56026,{"lat":398,"lon":397},[401,403],{"name":402,"role":78,"phone":71,"phoneExt":71,"email":71},"Ying Wang",{"name":402,"role":75,"phone":71,"phoneExt":71,"email":71},{"facility":405,"status":88,"city":406,"state":71,"zip":71,"country":91,"countryCode":92,"cosmosGeoPoint":407,"geoPoint":411,"contacts":412},"Tianjin Medical University Cancer Institute & Hospital","Tianjin",{"type":94,"coordinates":408},[409,410],117.17667,39.14222,{"lat":410,"lon":409},[413,415],{"name":414,"role":78,"phone":71,"phoneExt":71,"email":71},"Pei-Guo Wang",{"name":414,"role":75,"phone":71,"phoneExt":71,"email":71},{"type":75,"investigatorFullName":417,"investigatorTitle":418,"investigatorAffiliation":5,"oldNameTitle":71,"oldOrganization":71},"Jun Ma, MD","Professor",[420],{"name":421,"class":422},"Jiangsu Hengrui Pharmaceutical Co., Ltd.","INDUSTRY","100534507","phase-3-reduced-dose-radiotherapy-for-stage-iii-nasopharyngeal-carcinoma-based-on-the-treatment-response-100534507",false,"NCT06239727","Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response: an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial","Inclusion Criteria:\n\n1. Age: 18 Years to 65 Years;\n2. Eastern Cooperative Oncology Group performance status ≤1;\n3. Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma;\n4. Tumor staged as Stage III (T3N0 Excepted; AJCC 8th);\n5. Patients' lymph node without adverse features (no central necrosis, no muscle\u002Fskin invasion, no lymph node fusion);\n6. Normal bone marrow function: white blood cell count \\> 4×10\\^9\u002FL, hemoglobin \\> 90g\u002FL, platelet count \\> 100×10\\^9\u002FL;\n7. Normal liver and kidney function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine transaminase and aspartate transaminase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, creatinine clearance rate ≥ 60 ml\u002Fmin;\n8. Receive 3 cycles of indction chemotherapy (GP regimen + Camrelizumab);\n9. Plasma EBV DNA after the second cycle of concurrent chemotherapy: negative;\n10. Complete remission after 27 fractions of radiotherapy based on the MRI examination of the nasopharynx and neck (According to Response Evaluation Criteria in Solid Tumors 1.1);\n11. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule;\n12. Subjects with pregnancy ability must agree to use reliable contraceptive measures from screening to 1 year after treatment.\n\nExclusion Criteria:\n\n1. Hepatitis B virus surface antigen (HBsAg) positive and Hepatitis B virus DNA \\> 1000 copies\u002Fml;\n2. Anti-hepatitis C virus positive;\n3. Anti-human immunodeficiency virus (HIV) positive or diagnosed with acquired immune deficiency syndrome (AIDS);\n4. Active tuberculosis: active tuberculosis in the past 1 year should be excluded regardless with treatment, history of active tuberculosis over 1 year should be excluded except that previous regulatory anti-tuberculosis treatment is proved;\n5. Active, known or suspected autoimmune disease (including but not limited to uveitis, enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchiectasis). Exceptions are type I diabetes mellitus, hypothyroidism requiring hormone replacement therapy, skin disorders requiring no systemic treatment (such as vitiligo, psoriasis or alopecia);\n6. Previous interstitial lung disease or pneumonia requiring oral or intravenous steroid therapy;\n7. Chronic treatment with systemic glucocorticoid (dose equivalent to or over 10 mg prednisone per day) or any other form of immunosuppressive therapy. Subjects who used inhaled or topical corticosteroids were eligible;\n8. Uncontrolled heart disease, for example: 1) heart failure (NYHA level ≥ 2), 2) unstable angina, 3) myocardial infarction in past 1 year, 4) supraventricular or ventricular arrhythmia requiring treatment or intervention;\n9. Active infection requiring systemic treatment;\n10. Previous or concurrent with other malignant tumors, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary cancer;\n11. History of radiotherapy, except for non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma;\n12. Receive treatment for the local or regional disease other than that specified in the research plan;\n13. Pregnant or lactating women (pregnancy test should be considered for women with sexual life and fertility);\n14. Allergy to macromolecular protein preparations, or any component of Camrelizumab;\n15. Receiving live vaccine within 30 days of the initial Camrelizumab;\n16. Contraindications to MRI examination, for example: claustrophobia, allergy to MRI contrast;\n17. History of psychotropic disease, alcoholism or drug abuse, and other situation assessed by the investigators that may compromise the safety or compliance of patients, such as serious disease requiring timely treatment (including mental illness), severe laboratory abnormalities, or family-social risk factors.","ALL","18 Years","65 Years",{"count":434,"type":435},593,"ESTIMATED","INTERVENTIONAL",[438],"PHASE3","This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.",[441],"Nasopharyngeal Carcinoma",[443,444,445,446,68,447,448,449,450],"Radiotherapy","Dose","PD-1","Immune Checkpoint Inhibitor","Quality of Life","Personalised Therapy","Complication","Deintensification","2026-03-04",{"date":453,"type":454},"2026-03-06","ACTUAL",{"date":456,"type":454},"2024-03-01",{"date":458,"type":435},"2030-02-20",{"name":5,"class":6},26]